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Human papillomavirus (HPV) is a group of related 
viruses that cause warts on the arms, chest, hands feet, 
and mucous membranes. Genital HPV occurs on the 
mucous membranes, which are the moist surface 
layers of the body that are open to the outside, such as 
the vagina, anus, mouth, and throat. High-risk HPV 
types have been linked with and are known to cause 
cancer (American Cancer Society, 2015). High-risk or 
oncogenic human papillomaviruses cause most anal, 
vaginal, vulvar, penile, oropharyngeal cancers, and 
virtually all cervical cancers. Most HPV infections 
clear without treatment within 1 to 2 years, but 
infections that persist for many years can progress to 
pre-cancers or cancers (National Cancer Institute 
[NCI]), 2015). The Advisory Committee on 
Immunization Practices recommends routine 
vaccination of females aged 11-12 years with 3 doses 
of Cervarix®, Gardasil®, or Gardasil 9® and routine 
vaccination of males aged 11-12 years with 3 doses of 
Gardasil® or Gardasil 9®. Vaccination is also 
recommended for females aged 13 through 26 years 
and males aged 13 through 21 years who have not 
been vaccinated previously or who did not complete 3 
doses of the vaccine (Petrosky et al., 2015).  
 
Cervarix® (bivalent) prevents infection with HPV 
types 16 and 18; Gardasil® (quadrivalent) prevents 
infection with types 6, 11, 16, and 18; and Gardasil 
9® (9-valent) prevents infection with types 6, 11, 16, 
18, 31, 33, 45, 52, and 58, all of which cause anal, 
vulvar, vaginal and cervical pre-cancers and cancers. 
Either of the three vaccines can be used to prevent 
POPULATION SCIENCE 
ABSTRACT 
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infection with HPV types 16 and 18, which are 
responsible for 70% of cervical cancers and cause 
about half of vaginal, vulvar, and penile cancers (NCI, 
2015). Further, these vaccines prevent formation of 
anal, vulvar, vaginal, and cervical pre-cancers and 
cancers caused by HPV-16 and HPV-18.  
 
Other HPV types, such as HPV 31, 33, 45, 52, and 58, 
cause about 25% of cervical pre-cancers and 10% of 
invasive HPV-associated cancers. HPV types 6 and 11 
cause 90% of anogential warts and most cases of 
recurrent respiratory papillomatosis (Petrosky et al., 
2015). Further, HPV-16, which causes about 85% of 
all cases of anal cancer, has been linked to more than 
half of the cancers diagnosed in the oropharynx (NCI, 
2015). HPV vaccines, which protect against high-risk 
HPV types known to cause cancer, are most effective 
when given before an adolescent becomes sexually 
active. HPV transmission can also be reduced by 
screening for cervical cancer, using condoms, and 
limiting the number of sexual partners (American 
Cancer Society, 2015). Cervical cancer screening with 
a Papanicolaou (Pap) test can help find abnormal 
tissues or precancerous lesions at an early stage, 
which are treatable (NCI, n.d.). In the United States, 
cervical cancer screening guidelines recommend 
screening women ≥21 years old every 3 years with the 
Pap test alone and women ≥30 years every 5 years 
with a Pap test and an HPV DNA test (NCI, n.d.). 
 
The Centers for Disease and Control and Prevention 
(CDC) analyzed 2004-2008 data from the National 
Program of Cancer Registries (NPCR), the NCI, and 
Surveillance, Epidemiology, and End Results (SEER) 
program to determine the incidence of HPV-
associated cancers in the United States, including all 
50 states and the District of Columbia. During this 
timeframe, approximately 33,369 HPV-associated 
cancers were diagnosed annually in the United States-
- 12,080 among males and 21,290 among females. 
The national analysis showed that approximately 
26,000 new cancers were attributable to HPV (18,000 
among females and 8,000 among males) (Human 
Papillomavirus-Associated Cancers – U.S., 2012). 
The objective of the present research was to determine 
the incidence of HPV-associated cancers in Georgia 
(GA) by analyzing cancer registry data for GA from 
2008-2012, provide estimates on the HPV-associated 
cancers, and examine the incidence of HPV-




The incidence of HPV-associated cancers in GA 
during 2008-2012 were calculated from data obtained 
from the Georgia Department of Public Health, 
Division of Health Protection, Epidemiology 
Program, Chronic Disease, Healthy Behaviors and 
Injury Epidemiology Section of the Georgia 
Comprehensive Cancer Registry Unit (GCCR). Case 
definitions for HPV-associated cancers were based on 
CDC’s Morbidity and Mortality Weekly Report 
(MMWR) 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm61
15a2.htm: “Human Papillomavirus-Associated 
Cancers – United States, 2004-2008,” in order to 
analyze the burden of invasive cancers at specific 
anatomic sites known to be associated with HPV, 
including cancers of the cervix, vulva, vagina, penis, 
anus, and oropharynx. Additionally, included in the 
analyses were specific cell types known to contain 
HPV DNA; these were carcinoma of the cervix and 
squamous cell carcinoma (scc) for all other sites 
(Centers for Disease Control and Prevention, 2012). 
For oropharyngeal cancers specific sites included 
were those where HPV was most likely to be found: 
base of the tongue, tonsils, and other sites in the 
oropharynx. Age-adjusted rates and age-specific 
incidence rates were calculated per 100,000 persons 
using Statistical Analysis Software (SAS®) 9.4 and 
standardized to the 2000 U.S. Standard Population. 
Incidence rates were considered significant at p≤0.05. 
Based on previous reports, the percentage of each 
cancer found attributable to HPV was calculated by 
multiplying the average annual number of HPV-
associated cancers by the percentage of cancers 
attributable to HPV (Gillson et al., 2008). Data were 
analyzed by sex, age, race/ethnicity, and geographic 
location. Race/ethnicity categories included non-
Hispanic (NH) whites and NH blacks. The incidence 
of HPV-associated cancers by geography was 
calculated by use of 2013 Rural-Urban Continuum 
Codes used to classify metropolitan (metro) counties 
by the population size of their metro area and 
nonmetropolitan counties by degree of urbanization 
and adjacency to a metro area or areas. 
Metro>1million includes counties in metro areas of 1 
million population or more (N=29). Metro 250,000-1 
million includes counties in metro areas of 250,000 to 
1 million population (N=15). Metro<250,000 includes 
counties in metro areas of fewer than 250,000 
population (N=30). Smaller Urban includes urban 
population of 20,000 or more, adjacent to a metro 
area, Urban population of 20,000 or more, not 
adjacent to a metro area, Urban population of 2,500 to 
19,999, adjacent to a metro area, and Urban 
population of 2,500 to 19,999, not adjacent to a metro 
area (N=63). Rural includes completely rural or less 
than 2,500 urban population, adjacent to a metro area, 
and completely rural or less than 2,500 urban 
population, not adjacent to a metro area (N=22). 
Figure 1 shows the Metro, Metro Adjacent, and Rural 
Counties classification for GA. 
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Data Sources: Georgia Department of Public Health, Division of Health Protection, Epidemiology Program, Chronic Disease, 
Healthy Behaviors and Injury Epidemiology Section, Georgia Comprehensive Cancer Registry (2008-2012) 
Updated: January 2016 
Visit: http://dph.georgia.gov/georgia-comprehensive-cancer-registry for more information about cancer in Georgia. 
 
Figure 1. Metro, metro adjacent, and rural counties, Georgia, 2013 
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Total 1876 7.8 (7.5, 8.2) 447 1.7 (1.5, 1.8)
Age (yrs)
0-19 0 0.0 (0.0, 0.0) 0 0.0 (0.0, 0.0)
20-29 - - - - - -
30-39 32 1.0 (0.7, 1.3) - - -
40-49 253 7.0 (6.2, 7.9) 54 1.5 (1.1, 1.8)
50-59 694 8.3 (7.3, 9.3) 137 4.2 (3.5, 4.9)
60-69 613 30.5 (28.1, 32.9) 136 6.0 (5.0, 7.0)
70-79 228 23.1 (20.1, 26.1) 79 6.4 (5.0, 7.8)
≥80 54 12.8 (9.3, 16.2) 27 3.4 (2.1, 4.6)
Race/Ethnicity
Non-Hispanic Black 343 6.1 (5.4, 6.8) 96 1.3 (1.0, 1.5)
Non-Hispanic White 1493 9.0 (8.6, 9.5) 340 1.9 (1.7, 2.1)








During 2008-2012, 6,056 HPV-associated cancers 
were diagnosed in GA-- 2,408 among males and 3,648 
among females. For males, oropharyngeal cancer was 
the most common, with 1,876 cases annually (Table 
1). Males (age-adjusted rate (AAR) =7.8/100,000) 
were more than four times more likely to be 
diagnosed with oropharyngeal cancer than females 
(AAR=1.7/100,000). For both sexes, oropharyngeal 
cancer was significantly higher among NH whites 
(males: AAR=9.0/100,000; females: 
AAR=1.9/100,000) than NH blacks (males: 
AAR=6.1/100,000; females: AAR=1.3/100,000). Anal 
cancer was higher among females 
(AAR=2.2/100,000) than males (AAR=1.6/100,000) 
and was significantly higher among NH white females 
(AAR=2.6/100,000) compared to NH black females 
(AAR=1.5/100,000). However, anal cancer was 
higher (but not statistically different) among NH black 
males (AAR=1.9/100,000) compared to NH white 
males (AAR=1.5/100,000) (Table 1). 
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Total 353 1.6 (1.4, 1.7) 599 2.2 (2.1, 2.4)
Age (yrs)
0-19 0 0 (0.0,0.0) 0 0 (0.0,0.0)
20-29 - - - 0 0 (0.0,0.0)
30-39 30 0.9 (0.6, 1.2) - - -
40-49 112 3.2 (2.6, 3.7) 92 2.5 (2.0, 3.0)
50-59 97 1.1 (0.7, 1.4) 312 6.5 (5.7, 7.4)
60-69 63 3.2 (2.4, 4.0) 200 6.1 (5.0, 7.1)
70-79 31 3.3 (2.1, 4.5) 114 6.7 (5.3, 8.2)
≥80 18 4.3 (2.3, 6.2) 78 7.3 (5.5, 9.2)
Race/Ethnicity
Non-Hispanic Black 119 1.9 (1.6, 2.3) 109 1.5 (1.2, 1.8)




      Significant 
Data Sources: Georgia Department of Public Health, Division of Health Protection, Epidemiology 
Program, Chronic Disease, Healthy Behaviors and Injury Epidemiology Section, Georgia 
Comprehensive Cancer Registry (2008-2012) 
Updated: January 2016 
 
 
Penile cancer rates were higher, but not significant, 
among NH black males (AAR= 1.1/100,000) 
compared to NH white males (AAR= 0.8/100,000). 
Cervical cancer, with 1,940 cases, was the most 
common cancer among females (Table 1). The rate of 
cervical cancer was higher among NH black females 
than NH white females (AAR=8.8 /100,000 vs AAR= 
7.7/100,000). Rates of vulvar cancer were 
significantly higher among NH white females 
(AAR=2.5/100,000) than NH black females 
(AAR=1.5/100,000). Vaginal cancer rates were 
slightly higher among NH black females 
(AAR=0.7/100,000) compared to NH white females 
(AAR=0.4/100,000).  
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Total 179 0.9 (0.7, 1.0) 1940 7.7 (7.4, 8.1) 537 2.1 (1.9, 2.3) 125 0.5 (0.4, 0.6)
Age (yrs)
0-19 0 0 (0.0,0.0) _ _ _ 0 0 (0.0,0.0) 0 0 (0.0,0.0)
20-29 0 0 (0.0,0.0) 105 3.0 (2.5, 3.6) _ _ _ 0 0 (0.0,0.0)
30-39 _ _ _ 446 13.0 (11.8, 14.2) 29 0.9 (0.5, 1.2) _ _ _
40-49 25 0.7 (0.4, 1.0) 500 13.8 (12.6, 15.1) 93 2.5 (2.0, 3.0) _ _ _
50-59 32 1.1 (0.7, 1.4) 406 12.5 (11.2, 13.7) 103 3.2 (2.6, 3.8) 215 0.8 (0.5, 1.0)
60-69 52 2.6 (1.9, 3.4) 255 11.3 (9.9, 12.7) 123 5.4 (4.5, 6.4) 137 1.6 (1.1, 2.2)
70-79 44 4.7 (3.3, 6.0) 127 10.3 (8.5, 12.1) 103 8.4 (6.8, 10.0) 83 1.8 (1.0, 2.5)
≥80 19 4.5 (2.4, 6.5) 96 11.8 (9.5, 14.2) 83 10.3 (8.1, 12.5) 60 3.1 (1.9, 4.3)
Race/Ethnicity
Non-Hispanic Black 46 1.1 (0.7, 1.4) 639 8.8 (8.1, 9.5) 101 1.5 (1.2, 1.8) 47 0.7 (0.5, 0.9)
Non-Hispanic White 123 0.8 (0.7, 1.0) 1118 7.7 (7.2, 8.1) 414 2.5 (2.2, 2.7) 72 0.4 (0.3, 0.5)
Penile SCC Cervical Carcinoma Vulva SCC Vaginal SCC
 
 
*HPV-associated cancers are defined as cancers at specific anatomic sites and with specific cellular types in which HPV DNA frequently is 
found. Data are from the Georgia Cancer Registry. Only carcinomas are included for cervical cancer. Only SCCs are included for vulvar, vaginal, 
penile, anal, and oropharyngeal cancers. Anal cancers include SCCs coded to the rectum. All cell types (histology) were microscopically 
confirmed. Oropharyngeal sites and other definitions specified in: Centers for Disease Control and Prevention (2012). Oropharyngeal sites and 








Data Sources: Georgia Department of Public Health, Division of Health Protection, Epidemiology Program, Georgia Comprehensive Cancer 
Registry (2008-2012) 
Updated: January 2016 
Visit: http://dph.georgia.gov/georgia-comprehensive-cancer-registry for more information about cancer in Georgia. 
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In GA, 4,629 cancers that occurred during 2008-2012 
were attributable to HPV -- 1,574 among males and 
3,055 among females. The most common cancers 
attributable to HPV were oropharyngeal cancers 
(1,182) among males and cervical cancers (1,862) 
among females (Table 2). 
 
Males living in metro counties (250,000 to 1 million) 
had the highest oropharyngeal incidence rate 
compared to the state incidence rate; males living in 
rural counties had a significantly lower rate. Males 
living in smaller urban counties had the lowest anal 
SCC incidence rate. Males living in smaller urban 
counties had the highest penile SCC incidence rate 
and males living in metro counties (1 million or more) 




% Range Total number 5 Yrs Annual Average
Oropharynx
   Male 1876 63 (50-75) 1182 236
   Female 447 63 (50-75) 282 56
Anus
   Male 353 93 (86-97) 328 66
   Female 599 93 (86-97) 557 111
Penis 179 36 (26-47) 64 13
Cervix 1940 96 (95-97) 1862 372
Vulva 537 51 (37-65) 274 55
Vagina 125 64 (43-82) 80 16
Table 2. Estimated percentages and numbers of cancers attributable to human HPV by anatomic site and sex, 
Georgia, 2008-2012











Metro 1M+ 7.6 (7.1, 8.1) 1.6 (1.4, 1.8) 1.6 (1.4, 1.9) 2.1 (1.8, 2.3)
Metro 250K-1M 9.0 (7.9, 10.1) 2.0 (1.5, 2.5) 1.7 (1.2, 2.2) 2.2 (1.7, 2.8)
Metro <250K 8.6 (7.7, 9.6) 1.7 (1.3, 2.1) 1.5 (1.1, 1.9) 2.6 (2.1, 3.1)
Smaller urban 7.7 (6.8, 8.5) 1.9 (1.5, 2.3) 1.3 (0.9, 1.6) 2.3 (1.8, 2.7)
Rural 5.7 (4.1, 7.3) 1.8 (1.0, 2.7) - - 2.9 (1.8, 4.0)
Table 3. Age-adjusted incidence rates (2008-2012) by geography, Georgia
Oropharyngeal SCC Anal SCC
Male Female Male Female
 
 
Females living in metro counties (250,000 to 
1 million) had the highest oropharyngeal incidence 
rate, and females living in metro counties (1 million or 
more) had the lowest rate. Females living in rural 
counties had the highest anal SCC incidence rate, and 
females living in metro counties (1 million or more) 
had the lowest rate. Females living in smaller urban 
counties had a significantly higher cervical cancer 
incidence rate than females living in metro counties 
(1 million or more) and females living in metro 
counties (1 million or more) had the lowest rate. 
Females living in smaller urban counties had the 
highest vulvar SCC incidence rate, and females living 
in metro counties (less than 250,000) had the lowest 
rate. Females living in metro counties (250,000 to 
1 million) had the highest vaginal SCC incidence rate. 
Females living in all geographical areas in GA had 
similar rates of vaginal cancer (Table 3). 
 
 
*Source: Gillison et al., 2008. 
**The estimated number of HPV-attributable cancers calculated by multiplying the HPV-associated cancer counts from Table 1 
by the percentage of each cancer attributable to HPV. Estimates were rounded to the nearest tenth or hundredth. Female and male 
anal cancers do not equal the total number of anal cancers because of rounding. 
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Group Rate per 
100,000
95% CI Rate per 
100,000
95% CI Rate per 
100,000
95% CI Rate per 
100,000
95% CI
Metro 1M+ 0.8 (0.6, 1.0) 7.0 (6.6, 7.5) 1.8 (1.6, 2.1) 0.5 (0.3, 0.6)
Metro 250K-1M 0.9 (0.5, 1.3) 8.8 (7.7,9.9) 2.7 (2.1, 3.2) 0.6 (0.3, 0.9)
Metro <250K 0.8 (0.5, 1.1) 8.5 (7.6, 9.5) 1.7 (1.3, 2.1) 0.5 (0.3, 0.8)
Smaller urban 1.2 (0.9, 1.6) 8.9 (8.0, 9.9) 2.8 (2.3, 3.3) 0.5 (0.3, 0.7)
Rural - - 8.5 (6.1, 10.8) 2.7 (1.6, 3.9) - -
Penile SCC Cervical Carcinoma Vulvar SCC Vaginal SCC
 Significant  
The 2013 Rural-Urban Continuum was used to classify metropolitan (metro) counties by the population size of their 
metro area, nonmetropolitan counties by degree of urbanization and adjacency to a metro area or areas.  
Metro>1million includes counties in metro areas of 1 million population or more.  
Metro 250,000-1million includes counties in metro areas of 250,000 to 1 million population.  
Metro<250,000 includes counties in metro areas of fewer than 250,000 population.  
Smaller Urban includes urban population of 20,000 or more, adjacent to a metro area; Urban population of 20,000 or 
more, not adjacent to a metro area; Urban population of 2,500 to 19,999, adjacent to a metro area; and Urban population 
of 2,500 to 19,999, not adjacent to a metro area.  
Rural includes completely rural or less than 2,500 urban population, adjacent to a metro area, and completely rural or less 




In GA, incidence rates were calculated for specific 
sites known to be associated with HPV. The vulvar 
scc incidence rate for GA was higher than the U.S. 
rate (2.1/100,000 vs. 1.8/100,000). For GA, the 
incidence rates for vulvar, anal, and oropharyngeal scc 
among males and females were higher than U.S. rates. 
Vaginal and penile cancer incidence rates were 
slightly higher than those for the U.S., while cervical 
cancer incidence rates in GA were similar to the U.S. 
(Human Papillomavirus-Associated Cancers – U.S., 
2012). In GA from 2008-2012, females had a higher 
total number of cases than males (females, 3,648; 
males, 2,408) from 2008-2012. Slightly more than 
half of the total cases among females in GA were due 
to cervical cancer (1,940, 53.2%). Of 2,408 cases 
among males, more than half were from 
oropharyngeal cancer (1,876, 77.9%).  
 
According to the Behavioral Risk Factor Surveillance 
Survey in 2014, the cervical cancer screening rate for 
women aged 21-65, using 2012 screening guidelines, 
was 89% in GA overall, 88% among NH white 
females, and 95% among NH black females. Although 
cervical cancer screening rates were higher among 
NH black females, from 2008-2012 the age-adjusted 
cervical cancer incidence for this group was the 
highest in the state (9.2 per 100,000) (Georgia 
Comprehensive Cancer Registry, 2015). High cervical 
cancer screening rates could indicate a targeted effort 
in reaching and screening this population and may 
indicate a reduced access to screening services among 
this group and/or to a lack of follow up (Shavers & 
Brown, 2002; Fiscella et al., 2011). HPV vaccination 
should help reduce cervical cancer incidence rates. 
Barriers, including a lack of understanding of the 
HPV vaccine and age to vaccinate, along with strong 
physician recommendation must be addressed (Olshen 
et al., 2005; Brewer et al., 2007; Gilkey et al., 2015). 
According to the National Immunization Survey-
Teen, in 2014, in GA 65.4% of females and 41.2% of 
males aged 13-17 years received ≥1 dose of HPV 
vaccine, but only 47.1% of females and 21.0% of 
males aged 13-17 years received ≥3 doses. Nationally, 
60.0% of females and 41.7% of males aged 13-17 
years received ≥1 dose of HPV vaccine, but only 
39.7% of females and 21.6% of males aged 13-17 
years received ≥3 doses (Georgia Department of 
Public Health, 2015). Thus, few adolescents 
completed the recommended 3 doses of the HPV 
vaccine. Estimates of HPV vaccine uptake for females 
in GA were higher than national estimates. GA HPV 
vaccination estimates among males were similar to 
national estimates at ≥1 and ≥3 doses, but lower than 
estimates among GA females, indicating the need for 
increased promotion of the HPV vaccine among males 
(Georgia Department of Public Health, 2015). 
Increasing vaccination coverage among this age group 
is necessary to protect adolescents from HPV 
exposure. Further, improving cervical cancer 
screening should prevent the development of invasive 
cervical cancer. Among some parents with at least one 
child between ages 10 to 15 years old, there is a lack 
of understanding of the HPV vaccine (Olshen et al., 
2005). Acceptability is higher among parents who 
believe their child, at some point, would be exposed to 
HPV. Parents disagree on the age to vaccinate; some 
believed it would be easier to vaccinate at a younger 
age; some worry about encouraging unsafe sexual 
activity; and others want their child to take part in the 
decision to be vaccinated. Physician recommendation 
affects parental acceptance of vaccination. Similarities 
were found in a systematic review of HPV vaccine 
acceptability. As established in this review, parents 
had positive reactions to the HPV vaccine and were 
comfortable with it when they believed that the 
vaccine was effective, a physician recommended the 
vaccine, and they felt HPV infection was likely 
(Brewer et al., 2007).  
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The uptake of the HPV vaccine is reliant on physician 
recommendations. When making health decisions for 
their adolescents, parents generally trust what their 
health providers recommend. In a study performed in 
2014 (Gilkey et al., 2015), 776 U.S. physicians (53% 
pediatricians, 47% family medicine physicians) were 
surveyed. The study assessed perceptions and 
communication in administering vaccines to 11-12 
year old patients. Of the physicians, 73% reported that 
the HPV recommendation was highly important for 
adolescents, but only 13% viewed the HPV vaccine as 
being highly important to parents. Physicians also 
noted that the explanation for HPV vaccination took 
twice as long as that for Tdap.    
 
News media coverage of the HPV vaccine has 
affected the uptake of HPV vaccination. One study 
(Casciotti et al., 2014) found that news media 
coverage of HPV vaccination often presented HPV 
infection as unavoidable, used scare tactics, and 
presented cervical cancer as life threatening, which 
created fear. Additionally, 30% of articles presented 
the ideas that HPV vaccination promotes premarital 
sex and encourages sexual behavior. These issues 
affected the perceptions, feelings, and attitudes 
associated with HPV vaccination. 
 
The differing incidence rates for HPV-associated 
vulvar, vaginal, penile, and anal are not fully 
understood. Differences may be due to demographics, 
access to screening, tobacco use, or other 
environmental or specific factors relating to HPV. 
Differences in the incidence rate of oropharyngeal 
cancers may be due to tobacco use and alcohol use. 
HPV infection may also be involved. Differing risk 
factors, such as age and sexual behaviors may also be 
responsible for the varying incidence rates (Smith 
et al., 2010). Geographically, no apparent trend was 




HPV-associated cancers can be prevented by HPV 
vaccines, cervical cancer screening, and educating 
youth about risk factors associated with HPV 
infection. Surveillance of HPV-associated cancers 
using GA cancer registry data is needed to track future 
changes in incidence data due to administering the 
HPV vaccine, recommending cervical cancer 
screening, and educating youth in regard to risk 
factors. Increasing vaccination coverage among young 
adults will protect adolescents from HPV-related 
infections. Parents of adolescents take physician 
recommendations into consideration when making 
health decisions. However physician’s reluctance in 
recommending the HPV vaccine creates a missed 
opportunity for parents to consider HPV vaccination 
for their adolescent (Olshen et al., 2005; Brewer et al., 
2007; Gilkey et al., 2015).  
 
Provider education is needed so that HPV vaccination 
among adolescents can coincide with routine 
immunizations. Physician reluctance to 
recommending the HPV vaccine suggests a lack of 
assurance, understanding, and approach in which to 
discuss the vaccine with parents. Providing HPV 
vaccine communication strategies for healthcare 
providers can enable them to utilize opportunities to 
present the HPV vaccine to parents when discussing 
the adolescent immunization schedule (Gilkey et al., 
2015).  
  
Additionally, among parents of adolescents there is a 
lack of understanding about the nature of HPV and the 
HPV vaccine. Educational campaigns should aim to 
increase parents’ knowledge of HPV, the HPV 
vaccine, and the importance of completing the HPV 
vaccine dosage series before their teen engages in 
sexual activity (Brewer et al., 2007). HPV planning 
activities must address these barriers so that the 
vaccine is recommended with the routine adolescent 
immunization schedule and is promoted as a safe 
procedure that prevents HPV infections and HPV-
associated cancers. Further, there should be a 
continued effort to promote cervical cancer screening, 
especially to minority groups where disparities 
remain. Since there are no screening programs for 
oropharyngeal, anal, penile, vulvar, and vaginal HPV-
associated cancers, HPV vaccination can be an 
effective tool in the prevention of these cancers. 
 
In 2014, the Georgia Cancer Registry met the highest 
national data quality for cancer registry from the 
CDC, NPCR, the National Cancer Institute, SEER, 
and the North American Association of Central 
Cancer Registries, Inc. (NAACCR) (North American 
Association of Central Cancer Registries, Inc. [NAACCR], 
2016); (National Program of Cancer Registries [NPCR], 
2015). However, registry data do not capture HPV 
status. Estimates are provided in this report, but the 
number of HPV associated cancers and HPV-
attributable cancers may have been under- or over-
estimated. Smoking, demographics, and behavioral 
factors may also be involved in the variation in rates 
of HPV-associated cancers; these factors are not 
captured in cancer registry data.  
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